INS and type 2 diabetes mellitus: Recently, metformin reduced pro‐atherogenic TAMO in an experimental T2DM model via modulation of gut microbiota growth, and this might be a novel mechanism of the vasculoprotective effect of metformin against the development and progression of AS in T2DM via enhancement of insulin sensitivity and increased adiponectin expression.78